Article
A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of MEK1/2 Inhibitors in NRAS Mutant Melanoma.
Cancer research - 18 Jul 2022
Cai Weijia, Nguyen Mai Q, Wilski Nicole A, Purwin Timothy J, Vernon Mégane, Tiago Manoela, Aplin Andrew E
Abstract excerpt
Melanomas frequently harbor activating NRAS mutations. However, limited advance has been made in developing targeted therapy options for patients with NRAS mutant melanoma. MEK inhibitors (MEKi) show modest efficacy in the clinic and their actions need to be optimized. In this study, we performed a genome-wide CRISPR-Cas9-based screen and demonstrated that loss of phosphoinositide-dependent kinase-1 (PDPK1)...
Topics
- 1-Phosphatidylinositol 4-Kinase
- 3-Phosphoinositide-Dependent Protein Kinases
- Animals
- Cell Line, Tumor
- GTP Phosphohydrolases
- Humans
- MAP Kinase Kinase 1
- MAP Kinase Kinase 2
- Melanoma
- Membrane Proteins
- Mice
- Mitogen-Activated Protein Kinase Kinases
- Mutation